Study of Drug Response Testing Using Pleural Effusion Samples to Predict Outcomes in Lung Adenocarcinoma

What this Trial Is About

This observational study focuses on patients with lung adenocarcinoma who have malignant pleural effusions and require drainage due to shortness of breath. Researchers are evaluating whether ex-vivo drug sensitivity testing results align with genetic sequencing findings and if these tests can predict how patients will respond to treatments. This approach aims to improve understanding of the tumors behavior beyond what DNA sequencing alone can reveal. The study uses malignant pleural effusions as a source of viable tumor cells. These cells are isolated by identifying tumor markers and removing immune cells before being exposed to a range of FDA-approved targeted drugs in the lab. After 72 hours, cell viability is measured to assess drug effectiveness. While treatment decisions are not based on these tests during the study, clinical and follow-up data will be collected alongside drug response results. Participants undergo pleural drainage as part of their routine care, with additional samples collected for drug sensitivity testing. Researchers will analyze the correlation between drug response in the lab and genetic sequencing data within about three weeks. They will also track how well drug response predictions match clinical outcomes over up to two years. This study involves no investigational treatment and mainly involves observation and laboratory analyses.

Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma